studies

breast cancer (BC), anti-PD-(L)1 vs. non active control, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS) (extension)detailed resultsGeparNuevo, 2019 0.24 [0.03; 2.28] 0.24[0.03; 2.28]GeparNuevo, 201910%174NAnot evaluable events or deaths (EFS)detailed resultsKEYNOTE-522, 2020 0.63 [0.43; 0.93] 0.63[0.43; 0.93]KEYNOTE-522, 202010%1,174NAnot evaluable pCR detailed resultsGeparNuevo, 2019 1.45 [0.80; 2.63] KEYNOTE-522, 2020 13.60 [6.77; 27.33] 4.41[0.49; 39.52]GeparNuevo, 2019, KEYNOTE-522, 2020296%776moderatenot evaluable AE (any grade)detailed resultsKEYNOTE-522, 2020 0.25 [0.01; 4.74] 0.25[0.01; 4.74]KEYNOTE-522, 202010%1,170NAnot evaluable AE (grade 3-4)detailed resultsKEYNOTE-522, 2020 1.35 [1.01; 1.80] 1.35[1.01; 1.80]KEYNOTE-522, 202010%1,170NAnot evaluable AE leading to death (grade 5)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] 0.89[0.02; 45.40]GeparNuevo, 201910%174NAnot evaluable SAE (any grade)detailed resultsGeparNuevo, 2019 0.88 [0.47; 1.66] 0.88[0.47; 1.66]GeparNuevo, 201910%174NAnot evaluable TRAE (any grade)detailed resultsKEYNOTE-522, 2020 0.25 [0.03; 2.00] 0.25[0.03; 2.00]KEYNOTE-522, 202010%1,170NAnot evaluable TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 1.26 [0.96; 1.66] 1.26[0.96; 1.66]KEYNOTE-522, 202010%1,170NAnot evaluable TRAE leading to death (grade 5)detailed resultsKEYNOTE-522, 2020 1.50 [0.16; 14.43] 1.50[0.16; 14.43]KEYNOTE-522, 202010%1,170NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsKEYNOTE-522, 2020 2.16 [1.53; 3.05] 2.16[1.53; 3.05]KEYNOTE-522, 202010%1,170NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 10.08 [0.59; 173.00] 10.08[0.59; 173.00]KEYNOTE-522, 202010%1,170NAnot evaluable Alopecia TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 0.87 [0.36; 2.09] 0.87[0.36; 2.09]KEYNOTE-522, 202010%1,170NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 1.27 [0.91; 1.77] 1.27[0.91; 1.77]KEYNOTE-522, 202010%1,170NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 1.40 [0.65; 3.02] 1.40[0.65; 3.02]KEYNOTE-522, 202010%1,170NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 3.51 [0.43; 28.62] 3.51[0.43; 28.62]KEYNOTE-522, 202010%1,170NAnot evaluable Constipation TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 0.50 [0.01; 25.13] 0.50[0.01; 25.13]KEYNOTE-522, 202010%1,170NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 3.51 [0.43; 28.62] 3.51[0.43; 28.62]KEYNOTE-522, 202010%1,170NAnot evaluable Diabetes TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 1.99 [0.09; 44.34] 1.99[0.09; 44.34]KEYNOTE-522, 202010%1,170NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 1.71 [0.63; 4.67] 1.71[0.63; 4.67]KEYNOTE-522, 202010%1,170NAnot evaluable Dysgeusia TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 0.50 [0.01; 25.13] 0.50[0.01; 25.13]KEYNOTE-522, 202010%1,170NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 2.29 [0.94; 5.58] 2.29[0.94; 5.58]KEYNOTE-522, 202010%1,170NAnot evaluable Febrile neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 1.13 [0.82; 1.57] 1.13[0.82; 1.57]KEYNOTE-522, 202010%1,170NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 9.06 [0.52; 156.66] 9.06[0.52; 156.66]KEYNOTE-522, 202010%1,170NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 1.99 [0.09; 44.34] 1.99[0.09; 44.34]KEYNOTE-522, 202010%1,170NAnot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 8.04 [0.46; 140.38] 8.04[0.46; 140.38]KEYNOTE-522, 202010%1,170NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 3.00 [0.15; 59.96] 3.00[0.15; 59.96]KEYNOTE-522, 202010%1,170NAnot evaluable Increase AST TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 9.67 [1.29; 72.54] 9.67[1.29; 72.54]KEYNOTE-522, 202010%1,170NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 2.34 [1.13; 4.86] 2.34[1.13; 4.86]KEYNOTE-522, 202010%1,170NAnot evaluable Infusion-related reactions TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 2.53 [0.86; 7.45] 2.53[0.86; 7.45]KEYNOTE-522, 202010%1,170NAnot evaluable Leucopenia TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 0.76 [0.57; 1.03] 0.76[0.57; 1.03]KEYNOTE-522, 202010%1,170NAnot evaluable Myocarditis TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 1.99 [0.09; 44.34] 1.99[0.09; 44.34]KEYNOTE-522, 202010%1,170NAnot evaluable Myositis TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 0.50 [0.01; 25.13] 0.50[0.01; 25.13]KEYNOTE-522, 202010%1,170NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 2.64 [1.01; 6.94] 2.64[1.01; 6.94]KEYNOTE-522, 202010%1,170NAnot evaluable Nephritis TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 7.03 [0.40; 124.15] 7.03[0.40; 124.15]KEYNOTE-522, 202010%1,170NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 1.06 [0.82; 1.38] 1.06[0.82; 1.38]KEYNOTE-522, 202010%1,170NAnot evaluable Pancreatitis TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 4.00 [0.21; 75.85] 4.00[0.21; 75.85]KEYNOTE-522, 202010%1,170NAnot evaluable Peripheral neuropathy TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 1.88 [0.62; 5.72] 1.88[0.62; 5.72]KEYNOTE-522, 202010%1,170NAnot evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 1.20 [0.42; 3.43] 1.20[0.42; 3.43]KEYNOTE-522, 202010%1,170NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 1.50 [0.16; 14.43] 1.50[0.16; 14.43]KEYNOTE-522, 202010%1,170NAnot evaluable Pyrexia TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 4.02 [0.50; 32.22] 4.02[0.50; 32.22]KEYNOTE-522, 202010%1,170NAnot evaluable Rash TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 3.51 [0.43; 28.62] 3.51[0.43; 28.62]KEYNOTE-522, 202010%1,170NAnot evaluable Sarcoidosis TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 0.50 [0.01; 25.13] 0.50[0.01; 25.13]KEYNOTE-522, 202010%1,170NAnot evaluable Severe skin reaction TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 15.50 [2.11; 114.09] 15.50[2.11; 114.09]KEYNOTE-522, 202010%1,170NAnot evaluable Stomatitis TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 11.10 [0.65; 189.37] 11.10[0.65; 189.37]KEYNOTE-522, 202010%1,170NAnot evaluable Thyroiditis TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 1.99 [0.09; 44.34] 1.99[0.09; 44.34]KEYNOTE-522, 202010%1,170NAnot evaluable Uveitis TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 0.50 [0.01; 25.13] 0.50[0.01; 25.13]KEYNOTE-522, 202010%1,170NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsKEYNOTE-522, 2020 1.51 [0.59; 3.82] 1.51[0.59; 3.82]KEYNOTE-522, 202010%1,170NAnot evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed resultsGeparNuevo, 2019 1.79 [0.06; 54.10] 1.79[0.06; 54.10]GeparNuevo, 201910%174NAnot evaluable Abdominal pain AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] 0.89[0.02; 45.40]GeparNuevo, 201910%174NAnot evaluable Alopecia AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] 0.89[0.02; 45.40]GeparNuevo, 201910%174NAnot evaluable Anaemia AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.12; 6.46] 0.89[0.12; 6.46]GeparNuevo, 201910%174NAnot evaluable Arthralgia AE (grade 3-4)detailed resultsGeparNuevo, 2019 1.80 [0.16; 20.23] 1.80[0.16; 20.23]GeparNuevo, 201910%174NAnot evaluable Back pain AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.44 [0.01; 13.37] 0.44[0.01; 13.37]GeparNuevo, 201910%174NAnot evaluable Blood creatinine increased AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.05 [0.00; 0.89] 0.05[0.00; 0.89]GeparNuevo, 201910%174NAnot evaluable Constipation AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.05; 14.46] 0.89[0.05; 14.46]GeparNuevo, 201910%174NAnot evaluable Cough AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] 0.89[0.02; 45.40]GeparNuevo, 201910%174NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsGeparNuevo, 2019 5.49 [0.27; 111.35] 5.49[0.27; 111.35]GeparNuevo, 201910%174NAnot evaluable Dry skin AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] 0.89[0.02; 45.40]GeparNuevo, 201910%174NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] 0.89[0.02; 45.40]GeparNuevo, 201910%174NAnot evaluable Epistaxis AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] 0.89[0.02; 45.40]GeparNuevo, 201910%174NAnot evaluable Fatigue AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.47 [0.15; 1.45] 0.47[0.15; 1.45]GeparNuevo, 201910%174NAnot evaluable Febrile neutropenia AE (grade 3-4)detailed resultsGeparNuevo, 2019 1.82 [0.32; 10.20] 1.82[0.32; 10.20]GeparNuevo, 201910%174NAnot evaluable Headache AE (grade 3-4)detailed resultsGeparNuevo, 2019 1.79 [0.06; 54.10] 1.79[0.06; 54.10]GeparNuevo, 201910%174NAnot evaluable Hyperthyroidism AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] 0.89[0.02; 45.40]GeparNuevo, 201910%174NAnot evaluable Hypophysitis AE (grade 3-4)detailed resultsGeparNuevo, 2019 1.79 [0.06; 54.10] 1.79[0.06; 54.10]GeparNuevo, 201910%174NAnot evaluable Hypothyroidism AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] 0.89[0.02; 45.40]GeparNuevo, 201910%174NAnot evaluable Increase AST AE (grade 3-4)detailed resultsGeparNuevo, 2019 5.49 [0.27; 111.35] 5.49[0.27; 111.35]GeparNuevo, 201910%174NAnot evaluable Increased ALT AE (grade 3-4)detailed resultsGeparNuevo, 2019 1.20 [0.26; 5.51] 1.20[0.26; 5.51]GeparNuevo, 201910%174NAnot evaluable Infusion-related reaction AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] 0.89[0.02; 45.40]GeparNuevo, 201910%174NAnot evaluable Injury, poisoning and procedure AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.05; 14.46] 0.89[0.05; 14.46]GeparNuevo, 201910%174NAnot evaluable Leucopenia AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.84 [0.45; 1.57] 0.84[0.45; 1.57]GeparNuevo, 201910%174NAnot evaluable Myalgia AE (grade 3-4)detailed resultsGeparNuevo, 2019 1.82 [0.32; 10.20] 1.82[0.32; 10.20]GeparNuevo, 201910%174NAnot evaluable Nausea AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.06 [0.00; 1.05] 0.06[0.00; 1.05]GeparNuevo, 201910%174NAnot evaluable Neutropenia AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.83 [0.45; 1.52] 0.83[0.45; 1.52]GeparNuevo, 201910%174NAnot evaluable Peripheral neuropathy AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.88 [0.33; 2.33] 0.88[0.33; 2.33]GeparNuevo, 201910%174NAnot evaluable Pneumonitis AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] 0.89[0.02; 45.40]GeparNuevo, 201910%174NAnot evaluable Rash AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.05; 14.46] 0.89[0.05; 14.46]GeparNuevo, 201910%174NAnot evaluable Stomatitis AE (grade 3-4)detailed resultsGeparNuevo, 2019 3.62 [0.16; 81.50] 3.62[0.16; 81.50]GeparNuevo, 201910%174NAnot evaluable Thrombocytopenia AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.44 [0.04; 4.94] 0.44[0.04; 4.94]GeparNuevo, 201910%174NAnot evaluable Vomiting AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.05; 14.46] 0.89[0.05; 14.46]GeparNuevo, 201910%174NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-06-29 15:06 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 64,370,336,147,145,355,337,146,317,4,319,144,356,351,357,352,354,353,358,359,324,142,305,306,98,96,269,60,143,270,140,240,3 - treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons